[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Merus N.V. Common Shares (MRUS)

Merus N.V. shares hit a 1-year high of $XXXXX due to positive clinical trial results and analyst upgrades. Social media engagement is up, with many users discussing the stock and its potential.

About Merus N.V. Common Shares

Merus N.V. Common Shares (MRUS) is a biopharmaceutical company developing cancer therapeutics.
Merus N.V. Common Shares uses the ticker $MRUS for trading. Listed in the Stocks and category within the Healthcare sectors.

Insights #

Merus N.V. Common Shares (MRUS) trading volume is up XXXXX% from the previous week.
Merus N.V. Common Shares (MRUS) sentiment is up XXXXX% from the previous week.
Merus N.V. Common Shares Price hit a high of XXXXX for the hour
Merus N.V. Common Shares Price hit an all time of XXXXX for the hour

Price: $XXXXX #

Price 24-Hour Chart Data
The XXXXX% price surge in MRUS is driven by positive clinical trial results, analyst upgrades, and high social media engagement. The stock price is currently at $63.30, hitting a 1-year high, and the positive news indicates a likely continuation of the upward trend.

24-Hour	7-Day	30-Day
XXXX%	XXXX%	XXXX%

1-Year High: $XXXXX on 2025-07-25
1-Year Low: $XXXXX on 2025-04-08

AltRank: XXX #

AltRank Line Chart
AltRank 24-Hour Chart Data
Merus N.V. Common Shares (MRUS) is currently AltRank #320 based on combined combined social and market metrics Daily Average: XXX
1 Week: XXX -XXX
1 Month: XXX -XXX
6 Months: XXX -XXXXX
1 Year: XXX -XXX
1-Year High: XXXXX on 2025-05-13
1-Year Low: XX on 2025-05-25

Galaxy Score: XXXXX #

Galaxy Score Line Chart
Galaxy Score 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XX
1 Week: XX +4
1 Month: XX -X
6 Months: XX +34
1 Year: XX +19
1-Year High: XX on 2024-09-30
1-Year Low: XX on 2024-09-07

Engagements: XXXXX #

Engagements Line Chart
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXXX -XX%
6 Months: XXXXXXXXX +79%
1 Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-07-10
1-Year Low: XX on 2024-09-07

Social Network	X
Engagements	XXXXX

Mentions: XX #

Mentions Line Chart
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XXX +7.80%
1 Month: XXXXX +79%
6 Months: XXXXX +305%
1 Year: XXXXX +501%
1-Year High: XXXXX on 2025-07-10
1-Year Low: X on 2024-09-29

Social Network	X
Mentions	XXX

Creators: XX #

Creators Line Chart
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning Merus N.V. Common Shares (MRUS) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
1 Week: XXX no change
1 Month: XXXXX +7.10%
6 Months: XXXXX +478%
1 Year: XXXXX +775%
1-Year High: XXX on 2025-05-25
1-Year Low: X on 2024-09-29

The most influential creators that mention Merus N.V. Common Shares in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@SteveDJacobs	X	XXXXX	X	XXXXX
@MarcJacksonLA	X	XXXXX	X	XXXXX

Sentiment: XX% #

Sentiment Line Chart
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% +21%
1 Month: XXX% +6%
6 Months: XXX% no change
1 Year: XXX% +8%
1-Year High: XXX% on 2024-07-27
1-Year Low: X% on 2024-11-17

Most Supportive Themes

Positive Clinical Trial Data: (60%) Positive clinical trial results of Merus's drug, petosemtamab, particularly its high response and survival rates in head and neck cancer patients.
Analyst Price Target Increases: (20%) Several social media posts highlight analysts raising price targets for MRUS based on the promising clinical trial data.
Recommendation by Social User: (5%) Many social media users are sharing or following a user called @marohaalhob1.

Most Critical Themes

Trial Data Comparison Concerns: (1%) Some users are expressing concerns over comparing trial results with different patient populations and treatment contexts.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XXXXX	XX%	XXXXX	XX%	XX	X%

Total	XXXXX	XX%	XXXXX	XX%	XX	X%

Social Dominance: XXXXXXX% #

Social Dominance Line Chart
Social Dominance 24-Hour Chart Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
1 Week: XXXXXXX% -XXXXXXX%
1 Month: XXXXX% -XXXXX%
6 Months: XXXXX% +0.033%
1 Year: XXXXX% +0.023%
1-Year High: XXXXX% on 2025-05-25
1-Year Low: XXXXXX% on 2024-09-29

Market Dominance: XXXXXXX% #

Market Dominance Line Chart
Market Dominance 24-Hour Chart Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2024-08-05
1-Year Low: XXXXXX% on 2024-11-22

Market Cap: $XXXXXXXXXXXXX #

Market Cap Line Chart
Market Cap 24-Hour Chart Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
1 Week: $XXXXXXXXXXXXX +$5.60%
1 Month: $XXXXXXXXXXXXX +$24%
6 Months: $XXXXXXXXXXXXX +$76%
1 Year: $XXXXXXXXXXXXX +$36%
1-Year High: $XXXXXXXXXXXXX on 2025-07-25
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08

Top assets mentioned In the posts about Merus N.V. Common Shares in the last XX hours

Rainmaker Games (RAIN) MEI Pharma, Inc. (MEIP) Akropolis (AKRO) GSK plc (GSK) Tesla, Inc. (TSLA) Bitcoin Incognito (XBI) NuCypher (NU) DAOstack (GEN) Live Nation Entertainment, Inc. (LYV)

Top topics mentioned In the posts about Merus N.V. Common Shares in the last XX hours

$brk, $kidz, $cdio, $btai, $bntx, nvda, $mlgo, $rain, qbts, pltr, ibkr, $asst, soun, pep, rklb, bsx, spx, market cap, tem, $litm, gme, akro, onc, hut, prob, $mor, qqq, $psnl, asts, aap, qubt, alb, bfc, bbai, rblx, rna, $qntm, mor, $hnsa, $morf, avgo, $lgnd, twitch, 3m, 1m, 1w, thc, sei, $1b, rdnt, vrt, 1b, $bzai, $meip, $ampx, $goos, $gogo, $repl, $sndx, $tvtx, $akro, $veon, aur, spy, clsk, troo, hood, $gsk, $cmps, dltr, $tsla, $xbi, nem, oust, op, sonn, pki, $mygn, stocks healthcare, msft, smr, teva, matrix, $imcr, $nu, peg, $gen, $lyv, $qvcc, $myn, val, frog, meta, vst, amc, aa, nasdaq, gfi, mag, candle